Asher Chanan-Khan
Direktor/Vorstandsmitglied bei CELLECTAR BIOSCIENCES, INC.
Vermögen: - $ am 30.04.2024
Profil
Asher Alban Chanan-Khan is an Independent Director at Cellectar Biosciences, Inc. and a Director at Starton Therapeutics, Inc. He previously worked as a Director at Mayo Clinic Jacksonville and Jacksonville Zoological Society, Inc. He was also a Professor of Medicine and Oncology at Mayo Clinic College of Medicine & Science from 2011 to 2018.
Dr. Chanan-Khan holds a doctorate degree from New York University and Vagelos College of Physicians & Surgeons, and an undergraduate degree from Allama Iqbal Medical College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Asher Chanan-Khan
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 24.06.2021 |
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Asher Chanan-Khan
| Unternehmen | Position | Ende |
|---|---|---|
| Mayo Clinic College of Medicine & Science | Corporate Officer/Principal | 01.01.2018 |
Jacksonville Zoological Society, Inc.
 Jacksonville Zoological Society, Inc. Other Consumer ServicesConsumer Services Jacksonville Zoological Society, Inc. operates as a non-profit organization that engages in the management of a zoo. The company is headquartered in Jacksonville, FL. | Direktor/Vorstandsmitglied | - |
Mayo Clinic Jacksonville
 Mayo Clinic Jacksonville Hospital/Nursing ManagementHealth Services Mayo Clinic Jacksonville provides health care services. It specializes in transplant program, including bone-marrow, heart-lung, kidney, and pancreas. The company was founded in 1986 and is headquartered in Jacksonville, FL. | Direktor/Vorstandsmitglied | - |
Ausbildung von Asher Chanan-Khan
| New York University | Doctorate Degree |
| Allama Iqbal Medical College | Undergraduate Degree |
| Vagelos College of Physicians & Surgeons | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Mayo Clinic Jacksonville
Mayo Clinic Jacksonville Hospital/Nursing ManagementHealth Services Mayo Clinic Jacksonville provides health care services. It specializes in transplant program, including bone-marrow, heart-lung, kidney, and pancreas. The company was founded in 1986 and is headquartered in Jacksonville, FL. | Health Services |
Jacksonville Zoological Society, Inc.
Jacksonville Zoological Society, Inc. Other Consumer ServicesConsumer Services Jacksonville Zoological Society, Inc. operates as a non-profit organization that engages in the management of a zoo. The company is headquartered in Jacksonville, FL. | Consumer Services |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
